Psalmotoxin 1

Psalmotoxin 1 (PcTx1) is a protein toxin that can bind at subunit-subunit interfaces of acid-sensing ion channel 1a (ASIC1a) . Psalmotoxin 1 is a potent and slective ASIC1a inhibitor (IC 50 : 0.9 nM) by increasing the apparent affinity for H + of ASIC1a. Psalmotoxin 1 can induce cell apoptosis , also inhibits cell migration, proferliration and invasion of cancer cells. Psalmotoxin 1 can be used in the research of cancers, or neurological disease In Vitro Psalmotoxin 1 (20 nM, 125 s) inhibits ASIC1a currents by drastically shifting the steady-state desensitization curve to lower H + concentrations. Psalmotoxin 1 (30 nM) competes with Ca 2+ in binding to ASIC1a channels. Psalmotoxin 1 (100 or 200 ng, 24-72 h) significantly weakens the migration, proliferation and invasion of MCF-7 and MDA-MB-231 cells . Psalmotoxin 1 (100 ng/mL, 24 h) significantly inhibits acid-induced increases in intracellular calcium and LDH release, induces cell apoptosis and cell cycle arrest in nucleus pulposus cells (NPCs) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay Cell Line: MCF-7 and MDA-MB-231 cells Concentration: 100 or 200 ng Incubation Time: 24, 48, 72 h Result: Inhibited the cell migration, proliferation and invasion of breast cancer cells. Western Blot Analysis Cell Line: Nucleus pulposus cells (NPCs) Concentration: 100 ng/mL Incubation Time: 24 h Result: Decreased Bax and cleaved caspase-3 expression, and increased Bcl-2 expression. In Vivo Psalmotoxin 1 (i.c.v., 1 ng/kg, a single dose) is neuroprotective in a conscious model of stroke via direct inhibition of ASIC1a. Psalmotoxin 1 (tail vein injection, 10 ng/kg, daily for 7 days) inhibits tumor growth in breast cancer mice model. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male spontaneously hypertensive rats (SHR)Dosage: 1 ng/kg, a single dose. Administration: Intracerebroventricular (i.c.v.) injection Result: Reduced cortical and striatal infarct volumes measured 72 h post-stroke. Reduced the severity of motor deficit at 1 and 3 days after stroke compared to control rats. Displayed an anti-apoptotic effect in the occluded hemisphere (reduced stroke-induced caspase-3 positive cells). Animal Model: Female nude BALB/C mice (orthotopic implantation, MCF-7 and MDA-MB-231 cells)Dosage: 10 ng/kg, daily for 7 days. Administration: Tail vein injection Result: Inhibited breast tumor growth. Form:Solid IC50& Target:IC50: 0.9 nM (ASIC1a), 50 nM (ASIC1b, ASIC2a, and ASIC3)

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet